BrightSpring Health Services Inc

BrightSpring presented at the Wells Fargo Healthcare Conference a markedly accelerated EBITDA growth in the pharmacy segment (near 40% in 2025, >40% in H1 2026) and about 20% organic EBITDA growth in the provider business, supported by the integration of Amedisys LHC. Management highlighted investments in automation, AI and M&A as well as reduced leverage (near 2x EBITDA), which creates room for further acquisitions. The company expects 2026 to see the largest headwinds from IRA drug-price negotiations (around $15 million EBITDA impact), with a much smaller effect in 2027, and sees long-term tailwinds from LDD contracts, generic switches and expansion in the infusion and services business. » Plus sur de.investing.com

Shares of BrightSpring Health Services fell about 4.4% in after-hours trading after the announcement of a secondary placement of 15 million common shares by existing shareholders, including a subsidiary of Kohlberg Kravis Roberts and members of management. BrightSpring itself is not selling any shares and will not receive proceeds from the placement. At the same time, the company approved a share buyback of up to $60 million (up to 10% of the sold shares), to be executed concurrently with the placement; Goldman Sachs is acting as sole book-running manager. » Plus sur de.investing.com

Certain selling shareholders of BrightSpring, including a subsidiary of Kohlberg Kravis Roberts & Co. L.P. and members of management, intend to offer 15,000,000 common shares in a secondary placement. BrightSpring itself is not selling any shares; the proceeds will go entirely to the selling shareholders. In parallel, the company approved a buyback of up to 10% of the sold shares or a maximum of $60.0 million at the same placement price; Goldman Sachs & Co. LLC is acting as sole bookrunner. » Plus sur de.investing.com